{"doi":"10.1002/eji.202350580","title":"Interleukin‐2‐induced skin inflammation","abstract":"Recombinant human IL-2 has been used to treat inflammatory diseases and cancer; however, side effects like skin rashes limit the use of this therapeutic. To identify key molecules and cells inducing this side effect, we characterized IL-2-induced cutaneous immune reactions and investigated the relevance of CD25 (IL-2 receptor α) in the process. We injected IL-2 intradermally into WT mice and observed increases in immune cell subsets in the skin with preferential increases in frequencies of IL-4- and IL-13-producing group 2 innate lymphoid cells and IL-17-producing dermal γδ T cells. This overall led to a shift toward type 2/type 17 immune responses. In addition, using a novel topical genetic deletion approach, we reduced CD25 on skin, specifically on all cutaneous cells, and found that IL-2-dependent effects were reduced, hinting that CD25 - at least partly - induces this skin inflammation. Reduction of CD25 specifically on skin Tregs further augmented IL-2-induced immune cell infiltration, hinting that CD25 on skin Tregs is crucial to restrain IL-2-induced inflammation. Overall, our data support that innate lymphoid immune cells are key cells inducing side effects during IL-2 therapy and underline the significance of CD25 in this process.","journal":"European Journal of Immunology","year":2024,"id":433721,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":13,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9609,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":254161,"name":"Jarish N. Cohen","orcid":"0000-0002-6043-2177","position":1,"is_corresponding":false},{"id":58270,"name":"Susann Dehmel","orcid":"0000-0003-4860-2767","position":2,"is_corresponding":false},{"id":1239449,"name":"Vanessa Neuhaus","orcid":"0000-0002-0947-4929","position":3,"is_corresponding":false},{"id":133042,"name":"Dirk Schaudien","orcid":"0000-0001-7398-7262","position":4,"is_corresponding":false},{"id":604439,"name":"Armin Braun","orcid":"0000-0002-1142-1463","position":5,"is_corresponding":false},{"id":1210994,"name":"Katherina Sewald","orcid":"0000-0002-7804-4527","position":6,"is_corresponding":false},{"id":254162,"name":"Michael D. Rosenblum","orcid":"0000-0002-0462-5732","position":7,"is_corresponding":false},{"id":1239448,"name":"Charline Sommer","orcid":"0000-0002-6390-3878","position":0,"is_corresponding":true}],"reference_count":52,"raw_metadata":null,"created_at":"2026-07-19T01:59:49.434790Z","pmid":"38430129","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}